Genetic Analysis AS and Thalys Medical Technology Group Corporation announced that the parties have entered a Laboratory Developed Test (LDT) agreement to evaluate and develop innovative diagnostic solutions for the rapidly growing human microbiota market in China. Thalys will use its Shanghai-based Medical Lab group to further develop and distribute tests based on Genetic Analysis's GA-map® technology. In the first stage of the collaboration, Thalys Group will use its newly built Shanghai-based Independent Clinical Lab (ICL), Thalys MedLab to further develop and distribute tests based on Genetic Analysis' GA-map® Technology in China.

In 2021, Genetic Analysis launched the updated version of GA-map® Dysbiosis Test - the first CE-marked IVD test on the market providing microbiota profiles and dysbiosis status for IBS and IBD patients. The GA-map® Technology platform itself is based on an innovative Pre-Determined Targets approach (PDT).